47 related articles for article (PubMed ID: 16398402)
1. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Orsola A; Planas J; Catalán R; Reventós J
Int J Biol Markers; 2005; 20(4):209-16. PubMed ID: 16398402
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.
Lin GW; Yao XD; Zhang SL; Dai B; Ma CG; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Qin XJ; Ye DW
Asian J Androl; 2009 Jul; 11(4):443-50. PubMed ID: 19182820
[TBL] [Abstract][Full Text] [Related]
3. Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study.
Seo WI; Kang PM; Kim TH; Moon KH; Chung JM; Lee DH; Kim IY; Min K; Chung J; Kim W; Kang DI
World J Mens Health; 2014 Dec; 32(3):159-66. PubMed ID: 25606565
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Keizman D; Zahurak M; Sinibaldi V; Carducci M; Denmeade S; Drake C; Pili R; Antonarakis ES; Hudock S; Eisenberger M
Clin Cancer Res; 2010 Nov; 16(21):5269-76. PubMed ID: 20978144
[TBL] [Abstract][Full Text] [Related]
5. Remission Depth in Metastatic Hormone-Sensitive Prostate Cancer Is Associated With Prognosis in Patients With Initial Prostate-Specific Antigen Values Above 100 Ng/ML.
Azuma T; Katsumata A; Kano M; Tsumura K
Cureus; 2024 Feb; 16(2):e54036. PubMed ID: 38481910
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy.
İnci BK; Gürler F; Sütcüoğlu O; Baştuğ V; Yazıcı O; Üner A; Özet A; Özdemir N
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S845-S850. PubMed ID: 38102905
[TBL] [Abstract][Full Text] [Related]
7. The Value of Combined Detection of Serum PSA, MALAT1 and TMPRSS2-ETV1 in Evaluating the Progress and Prognosis of Prostate Cancer.
Zhao G; Pan Z; Wang P
Arch Esp Urol; 2023 Oct; 76(8):555-562. PubMed ID: 37960954
[TBL] [Abstract][Full Text] [Related]
8. A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma.
Lin YH; Chen CL; Hou CP; Chang PL; Tsui KH
Acta Pharmacol Sin; 2011 Apr; 32(4):537-42. PubMed ID: 21399652
[TBL] [Abstract][Full Text] [Related]
9. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients.
Wenzel M; Hoeh B; Hurst F; Koll F; Cano Garcia C; Humke C; Steuber T; Tilki D; Traumann M; Banek S; Chun FKH; Mandel P
Prostate; 2024 May; ():. PubMed ID: 38812332
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis.
Kan HC; Hou CP; Lin YH; Tsui KH; Chang PL; Chen CL
Onco Targets Ther; 2017; 10():2943-2949. PubMed ID: 28652776
[TBL] [Abstract][Full Text] [Related]
11. The evolving biology and treatment of prostate cancer.
Taichman RS; Loberg RD; Mehra R; Pienta KJ
J Clin Invest; 2007 Sep; 117(9):2351-61. PubMed ID: 17786228
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Prostate Cancer With Reticular Micronodular Opacities of Lung: A Case Report.
Bojja S; Javed N; Aziz MA; Fortuzi K; Khaja M
Cureus; 2023 Jul; 15(7):e42698. PubMed ID: 37654947
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is It Prognostic or Predictive?
Spratt DE
J Clin Oncol; 2024 May; ():JCO2302689. PubMed ID: 38743913
[No Abstract] [Full Text] [Related]
14. The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients.
Sasaki T; Sugimura Y
J Clin Med; 2018 Dec; 7(12):. PubMed ID: 30567361
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.
Afriansyah A; Hamid ARAH; Mochtar CA; Umbas R
F1000Res; 2018; 7():246. PubMed ID: 29904592
[No Abstract] [Full Text] [Related]
16. Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer.
Myung JK; Wang G; Chiu HH; Wang J; Mawji NR; Sadar MD
PLoS One; 2017; 12(3):e0174134. PubMed ID: 28306720
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
18. Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Prostate Int; 2015 Mar; 3(1):10-5. PubMed ID: 26157761
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer.
Hong SY; Cho DS; Kim SI; Ahn HS; Kim SJ
Korean J Urol; 2012 Sep; 53(9):607-13. PubMed ID: 23060997
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
